0
0
Read Time:8 Minute, 28 Second
The Tissue Diagnostics Market is projected to reach $8.52 billion by 2029, at a CAGR of 7.4% from 2022 to 2029. Tissue diagnostics involves the study of tissue to diagnose disease and determine the type of the tissue, whether it’s cancerous, and the characteristics of observed cancer. Furthermore, it uses instruments such as slide staining systems, slide scanners, tissue processing systems, embedding systems, and tissue microarrays. This study is used in hospitals, reference laboratories, research institutes, pharmaceutical companies, and contract research organizations
The growth of this market is mainly attributed to the rising global prevalence of cancer, the availability of biomarkers & biomarker research for cancer diagnosis & therapy, recommendations/guidelines and programs for cancer screening, the growing number of clinical trials for cancer drugs, the availability of advanced tissue-based companion diagnostic tests, and the rising global geriatric population. Moreover, the rising focus on personalized healthcare, adoption of digital pathology & automation in tissue diagnostics, and emerging economies offer significant opportunities for market growth.
Here are the top 10 companies operating in the Tissue Diagnostics Market
F. Hoffmann-La Roche Ltd. (Switzerland)
Founded in 1896 and established in Basel, Switzerland, F. Hoffmann-La Roche Ltd. is a research-based healthcare company engaged in developing innovative medicines and providing diagnostic solutions. The company operates through two business segments, namely, Pharmaceuticals and Diagnostics, and offers centralized and point-of-care kits & reagents, advanced staining reagents, molecular diagnostic tests, and blood screening tests through its Diagnostics division. The Diagnostics segment is further subsegmented into Core Lab, Molecular Lab, Point of Care, Diabetes Care, and Pathology Lab. This division manufactures equipment & reagents for research & medical diagnostic applications.
F. Hoffman-La Roche Ltd. operates in the tissue diagnostics market through its Pathology Lab segment and offers diagnostics solutions for tissue biopsies and companion diagnostics. The company has 20 manufacturing sites and 27 R&D sites engaged in pharmaceuticals and diagnostics operations worldwide.
Thermo Fisher Scientific Inc. (U.S.)
Founded in 2006 and headquartered in Massachusetts, U.S., Thermo Fisher Scientific Inc. is a biotechnology company specializing in life sciences research, improving patient diagnostics, and increasing laboratory productivity. The company operates through four business segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. Thermo Fisher offers diagnostic test kits, reagents, culture media, instruments, and associated products for customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories through its Specialty Diagnostics segment. This segment has five primary businesses: Clinical Diagnostics, Immunodiagnostics, Microbiology, Transplant Diagnostics and Healthcare Market Channel. In June 2019, Thermo Fisher Scientific sold its Anatomical Pathology business to PHC Holdings Corporation (Japan), which primarily offered products for cancer diagnosis & medical research in histology, cytology, and hematology applications.
The company has a direct presence through its regional offices and production sites in various countries, including the U.S., Mexico, Brazil, Germany, Belgium, Austria, the U.K., Italy, the Netherlands, South Africa, UAE, India, China, Japan, Australia, and the Republic of Korea.
Founded in 1888 and headquartered in Illinois, U.S., Abbott Laboratories is engaged in discovering, developing, manufacturing, and selling healthcare products. The company offers a wide range of products to the diagnostics, medical devices, nutrition, and branded generic pharmaceuticals markets. It operates globally through four business segments, namely, Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Abbott operates in the tissue diagnostics market through its Diagnostic segment. The Diagnostic segment is further subsegmented into Core Laboratory, Molecular Diagnostics, Point Of Care, Informatics and Automation Solutions, and Rapid Diagnostics. The company offers tissue diagnostics products through the Molecular Diagnostics subsegment.
The company has a wide geographic presence and a strong distribution network in various countries through direct and indirect channels. The company has 90 manufacturing facilities globally, of which 24 manufacturing sites are engaged in developing diagnostic products.
Danaher Corporation (U.S.)
Founded in 1969 and headquartered in Washington, D.C., U.S., Danaher Corporation is engaged in designing, manufacturing, and marketing medical, professional, industrial, and commercial products & services for various end users. The company operates through three business segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The company offers a wide range of products, reagents, and consumables in the tissue diagnostics market through its Diagnostics segment. The products offered by the company are used in various healthcare settings such as hospitals, physicians’ offices, reference laboratories, and other critical care settings to diagnose diseases. Its Diagnostics segment is subsegmented into Clinical Lab Diagnostics, Critical Care Diagnostics, and Anatomical & Pathological Diagnostics. Furthermore, the company offers tissue diagnostics products through the Leica Biosystems brand.
Danaher Corporation has a total of 212 R&D, manufacturing, sales, distribution, service, and administrative facilities in more than sixty countries worldwide. Its manufacturing facilities are in North America, Europe, Asia, and Australia. The company has a global presence through its subsidiaries in various countries, including Austria, Belgium, Canada, China, Denmark, France, Germany, India, Japan, Korea, Switzerland, and the U.K.
Founded in 1984 and headquartered in Venlo, Netherlands, QIAGEN N.V. is engaged in the development & sales of instruments, consumables, and digital bioinformatics solutions for oncology, infectious diseases, sexual & reproductive health, TB management, precision diagnostics, and point-of-care testing research. The company operates through two business segments: Molecular Diagnostics and Life Sciences. The company offers tissue diagnostics through its Molecular Diagnostics segment. Through this segment, Qiagen N.V. offers a wide range of molecular diagnostic technologies, including automated systems, assays, markers, and reagents used in the diagnosis of cancer and infectious diseases.
The company has a strong distribution network with distribution partners spread across 60 countries worldwide. QIAGEN N.V. offers its products to more than 500,000 customers and has 35 subsidiaries operating in 35 countries, including the U.S., Canada, Germany, Spain, the U.K., France, Italy, the Netherlands, Sweden, Turkey, Sweden, Brazil, Mexico, China, Hong Kong, Taiwan, South Korea, India, and South Africa. Furthermore, the company has manufacturing and production facilities in Germany, the U.S., the U.K., and China.
Meticulous Research in its latest publication on Tissue Diagnostics Market has predicted the growth of 7.4% during the forecast year 2022-2029
Becton, Dickinson and Company (U.S.)
Founded in 1897 and headquartered in New Jersey, U.S., Becton, Dickinson and Company (BD) is a medical technology company that manufactures and sells a wide range of medical devices, laboratory equipment, and diagnostic products used by healthcare institutions, clinical laboratories, pharmaceutical companies, and research centers. The company operates through three business segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Life Sciences segment offers products through two major divisions: Integrated Diagnostic Solutions (Diagnostic Systems and Preanalytical Systems) and Biosciences. The company operates in the tissue diagnostics market through the Biosciences category and offers numerous products for clinical and industrial applications.
BD has a direct presence in the U.S., Brazil, Canada, China, France, Spain, the U.K., Germany, Hungary, India, Ireland, Israel, Italy, Japan, Mexico, the Netherlands, and Singapore through its manufacturing and sales operations. Its R&D facilities are located globally, including in China, France, India, Ireland, the U.S., and Singapore. The company also has a wide distribution network globally. It markets its products through independent distribution channels and directly to hospitals, healthcare institutions, and independent sales representatives.
Established in 1998 and headquartered in Cambridge, U.K., Abcam plc is engaged in the identification, development, and distribution of high-quality biological reagents and tools used in the study of biological pathways critical for scientific research, diagnostics, and drug discovery. Its key customers include scientists and researchers in academic institutions, research institutes, and pharmaceutical, biotechnology and diagnostics companies. The company’s product offerings consist of primary antibodies, secondary antibodies, ELISA and matched antibody pairs, knockout cell lines and lysates, multiplex assays, agonists, antagonists, activators and inhibitors, and proteins. Abcam operates globally through 14 physical locations.
Agilent Technologies (U.S.)
Incorporated in 1999 and headquartered in California, U.S., Agilent Technologies provides application-focused solutions to the life sciences, diagnostics, and applied chemical markets. It operates through three business segments: Life Sciences & Applied Markets, Diagnostics and Genomics, and Agilent CrossLab Business. The company offers tissue diagnostics through its Diagnostics and Genomics segment. The Diagnostics and Genomics segment include genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership and biomolecular analysis businesses.
Agilent has primary R&D and manufacturing sites across the U.S., Australia, China, Denmark, Germany, Italy, Japan, Malaysia, Singapore, and the U.K. The Diagnostics and genomics segment has manufacturing and R&D facilities in Belgium, Denmark, Germany, Malaysia, and the U.S.
Founded in 1668 and headquartered in Darmstadt, Germany, Merck is a science and technology company. The company operates through three segments, namely, Healthcare, Life Sciences, and Electronics, and offers more than 300,000 products in the tissue diagnostics market through its Life Sciences segment.
The Life Science business sector has 52 manufacturing sites across the globe with more than 100 distribution centers. The sector has corporate offices, manufacturing units, and distributors across Argentina, Germany, France, Romania, Colombia, Japan, Brazil, Belgium, Croatia, the U.S., and Iraq.
Sakura Finetek Japan Co., Ltd. (Japan)
Established in 2001 and headquartered in Tokyo, Japan, Sakura Finetek Japan is a healthcare-based pathology automation company specializing in cancer diagnosis. The company engages in R&D, manufacture, sales and export/import of medical specimen preparation instruments, consumables, reagents, and other related products in the field of clinical pathology (histology, cytology, immunology). Sakura’s regional office is in Selangor Darul Ehsan, Malaysia.
Authoritative Research on the Tissue Diagnostics Market – Global Opportunity Analysis and Industry Forecast (2022-2029)
Need more information? Meticulous Research®’s new report Tissue Diagnostics Market covers each of these companies in much more detail, providing analysis on the following:
- Recent financial performance of Tissue Diagnostics Market
- Key products
- Significant company strategies
- Partnerships and acquisitions
The Comprehensive Tissue Diagnostics Market report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
